A detailed history of Israel Englander (Millennium Management LLC) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 138,504 shares of ALNY stock, worth $37.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
138,504
Previous 4,500 2977.87%
Holding current value
$37.8 Million
Previous $672,000 4908.33%
% of portfolio
0.02%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$143.31 - $247.0 $9.14 Million - $15.8 Million
-63,774 Reduced 31.53%
138,504 $33.7 Million
Q1 2024

May 15, 2024

BUY
$146.51 - $198.2 $24.3 Million - $32.9 Million
165,742 Added 453.64%
202,278 $30.2 Million
Q4 2023

Feb 14, 2024

SELL
$151.41 - $196.57 $5.82 Million - $7.56 Million
-38,444 Reduced 51.27%
36,536 $6.99 Million
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $9.55 Million - $10.9 Million
51,606 Added 220.78%
74,980 $14.2 Million
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $4.27 Million - $5.51 Million
23,374 New
23,374 $4.68 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $23.3 Million - $39 Million
168,318 Added 3780.73%
172,770 $34.6 Million
Q2 2022

Aug 15, 2022

SELL
$120.42 - $169.29 $7.17 Million - $10.1 Million
-59,505 Reduced 93.04%
4,452 $649,000
Q1 2022

May 16, 2022

SELL
$127.18 - $173.91 $2.47 Million - $3.38 Million
-19,460 Reduced 23.33%
63,957 $10.4 Million
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $11.4 Million - $15 Million
71,585 Added 605.01%
83,417 $14.1 Million
Q3 2021

Nov 15, 2021

BUY
$169.75 - $207.73 $290,442 - $355,426
1,711 Added 16.91%
11,832 $2.23 Million
Q2 2021

Aug 16, 2021

SELL
$128.63 - $176.89 $8.45 Million - $11.6 Million
-65,659 Reduced 86.64%
10,121 $1.72 Million
Q1 2021

May 17, 2021

SELL
$126.83 - $175.69 $5.65 Million - $7.83 Million
-44,563 Reduced 37.03%
75,780 $10.7 Million
Q4 2020

Feb 16, 2021

BUY
$122.97 - $147.0 $14.2 Million - $16.9 Million
115,143 Added 2214.29%
120,343 $15.6 Million
Q3 2020

Nov 16, 2020

BUY
$121.19 - $165.49 $101,678 - $138,846
839 Added 19.24%
5,200 $757,000
Q2 2020

Aug 14, 2020

SELL
$104.21 - $156.44 $10 Million - $15.1 Million
-96,410 Reduced 95.67%
4,361 $646,000
Q1 2020

May 14, 2020

SELL
$93.12 - $133.99 $1.63 Million - $2.34 Million
-17,491 Reduced 14.79%
100,771 $11 Million
Q4 2019

Feb 14, 2020

SELL
$74.51 - $124.23 $7.37 Million - $12.3 Million
-98,962 Reduced 45.56%
118,262 $13.6 Million
Q3 2019

Nov 14, 2019

BUY
$70.9 - $87.82 $4.48 Million - $5.55 Million
63,166 Added 41.0%
217,224 $17.5 Million
Q2 2019

Aug 14, 2019

BUY
$65.86 - $92.79 $10.1 Million - $14.3 Million
154,058 New
154,058 $11.2 Million
Q1 2019

May 14, 2019

SELL
$72.76 - $93.45 $827,499 - $1.06 Million
-11,373 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$62.67 - $88.33 $712,745 - $1 Million
11,373 New
11,373 $829,000
Q3 2018

Nov 14, 2018

SELL
$87.52 - $122.67 $190,968 - $267,665
-2,182 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$88.31 - $107.8 $192,692 - $235,219
2,182 New
2,182 $215,000
Q4 2017

Feb 14, 2018

SELL
$114.49 - $139.98 $5.85 Million - $7.16 Million
-51,125 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$72.53 - $118.27 $3.71 Million - $6.05 Million
51,125
51,125 $6.01 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $33.6B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.